| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 09/09/2005 | CA2555413A1 An immunoreactive 38-kda ferric binding protein of ehrlichia canis and uses thereof |
| 09/09/2005 | CA2555245A1 Antisense oligonucleotide modulation of stat3 expression |
| 09/09/2005 | CA2554870A1 Long-acting solid formulation comprising triptorelin acetate |
| 09/09/2005 | CA2554486A1 Treatment of bacterial infections |
| 09/09/2005 | CA2548220A1 Use of mda-7 to inhibit infection by pathogenic organisms |
| 09/09/2005 | CA2546843A1 Compounds and methods for increasing neurogenesis |
| 09/09/2005 | CA2543888A1 Monomethylvaline compounds capable of conjugation to ligands |
| 09/08/2005 | US20050197707 Collagen-based materials and methods for augmenting intervertebral discs |
| 09/08/2005 | US20050197497 Used to improve the therapeutic efficacy of current cancer treatment; sensitizing cancerous cells to treatment with conventional anti-tumor drugs |
| 09/08/2005 | US20050197496 Isolating preferential polypeptides from solution using transmembrane pressure, crossflow velocity, sample viscosity and solute concentration |
| 09/08/2005 | US20050197495 purification of transferrins using surfactants, antioxidants and flavonoids, than drying the pure glycoproteins |
| 09/08/2005 | US20050197493 Fibrinogen purification |
| 09/08/2005 | US20050197491 Comprises brain glycoprotein for use in identifying modulators which can be used in diagnosis and treatment of nervous system disorders |
| 09/08/2005 | US20050197381 methods of treating inflammatory-related diseases associated with pro-inflammatory cytokine expression and/or reduced expression of anti-inflammatory cytokines. The method typically comprises administration of one or more compounds selected from isoindigo, indigo, indirubin, or derivatives thereof |
| 09/08/2005 | US20050197322 Compounds capable of binding to proteins constituting or associated with cytoskeletal elements, and their applications for the manufacture of medicaments |
| 09/08/2005 | US20050197318 Acidic oligosaccharide fragments produced by marine sponges and sea urchin embryos; potent stimulators of natural killer cells and gamma delta T cells; cancer, viral infections |
| 09/08/2005 | US20050197314 Synergistic combination of immunostimulatory CpG oligonucleotides and the immunopotentiating cytokine Flt3 ligand; immunotherapy of tumors, viral infections; cancer vaccines |
| 09/08/2005 | US20050197313 Multiple promoter expression cassettes for simultaneous delivery of RNAi agents |
| 09/08/2005 | US20050197309 Antisense modulation of dual specific phosphatase 5 expression |
| 09/08/2005 | US20050197307 Antagonizing interaction between polynucleotide sequence 1 and interferon regulatory factor 1 (IRF 1); herpes virus infections |
| 09/08/2005 | US20050197306 DNA vaccines encoding heat shock proteins |
| 09/08/2005 | US20050197301 3,4-(cyclopentyl)-fused proline compounds as inhibitors of hepatitis C virus NS3 serine protease |
| 09/08/2005 | US20050197300 Microdose therapy |
| 09/08/2005 | US20050197299 Peptidomimetic protease inhibitors |
| 09/08/2005 | US20050197298 Water soluble, prevention of neovascularization |
| 09/08/2005 | US20050197297 Method for increasing the serum half-life of a biologically active molecule |
| 09/08/2005 | US20050197296 Agents for preventing and treating thrombocytopenia |
| 09/08/2005 | US20050197295 Modified annexin proteins and methods for preventing thrombosis |
| 09/08/2005 | US20050197294 Administering human parathyroid hormone (PTH) with calcium and/or vitamin D; post-menopausal, steroid-induced osteoporosis |
| 09/08/2005 | US20050197293 Use of an IL-1 antagonist for treating arthritis |
| 09/08/2005 | US20050197292 Inhibiting the release of cytokines from immune cells by contacting the cells with a composition comprising a CG57008 polypeptide; for preventing and/or treating inflammatory and autoimmune diseases; asthma, allergy, atopic eczema, inflammatory bowel disease, systemic lupus erythematosus, arthritis |
| 09/08/2005 | US20050197290 Useful in extending the in vivo circulating life of biologically active materials; bicine linker allows for the manipulation of the hydrolysis rate of the prodrug, thereby releasing the native entities at various rates in vivo as well as in vitro |
| 09/08/2005 | US20050197289 Therapeutic preparations of tachykinins, and more specifically sialokinins, for treating various types of abnormal cellular proliferation conditions in regions of tissue within body of patient; for therapy of tumor, wart, hyperproliferative cellular conditions |
| 09/08/2005 | US20050197288 Administering GH-releasing factor (GRF) and analogs (hexenoyl trans-3)hGRF(1-44)NH2 for altering a lipid parameter |
| 09/08/2005 | US20050197287 Methods for affecting body composition |
| 09/08/2005 | US20050197286 Method for control of depression using c terminal growth hormone (gh) fragment |
| 09/08/2005 | US20050197285 Human secreted proteins |
| 09/08/2005 | US20050197284 Providing acute neuroprotection by contacting neuronal cells with erythropoietin or active fragment or analog thereof close to or subsequent to time of excitatory insult and contacting cells with insulin-like growth factor, thereby producing synergistic acute neuroprotective effect; Alzheimer's disease |
| 09/08/2005 | US20050197283 Compositions containing beta 2-glycoprotein I for the prevention and/or treatment of vascular disease |
| 09/08/2005 | US20050197282 Compositions and methods for treatment of psoriasis |
| 09/08/2005 | US20050197281 Pharmaceutical combination preparations containing erythropoietin and modified haemoglobins |
| 09/08/2005 | US20050196860 Novel EPS8 compounds for therapy and diagnosis and methods for using same |
| 09/08/2005 | US20050196858 Isolation, selection and propagation of animal transgenic stem cells |
| 09/08/2005 | US20050196852 Antibodies to calcium independent cytosolic phospholipase A2/B enzymes |
| 09/08/2005 | US20050196839 Beta-secretase enzyme compositions and methods |
| 09/08/2005 | US20050196838 Reduced immunogenicity; increased affinity and avidity; improved cell culturing |
| 09/08/2005 | US20050196831 Human G-protein chemokine receptor (CCR5) HDGNR10 |
| 09/08/2005 | US20050196808 Products and processes for modulating peptide-peptide binding domain interactions |
| 09/08/2005 | US20050196806 Prostate specific antigen oligoepitope peptide |
| 09/08/2005 | US20050196802 peptide of given amino acid sequence related to the sulfotransferase drug-metabolizing enzyme subfamily; use drug screening |
| 09/08/2005 | US20050196798 Nucleoside triphosphate diphosphohydrolase (NTPDASE 8) and uses thereof |
| 09/08/2005 | US20050196793 Using aberrant expression of caudal type homeobox transcription factor 2 (CDX2) as diagnostic indicator of stomach or esophageal cell proliferative disorers |
| 09/08/2005 | US20050196783 Nucleotide sequences coding r-ounidabout (robo) regulatory protein (SLIT polypeptides) for use in treatment and prevention of nervous system disorders; nerve cell function modulators |
| 09/08/2005 | US20050196772 Nucleotide sequences coding lysosomal membrane glycoprotein for use as tool in prevention and treatment of bone disorders |
| 09/08/2005 | US20050196767 siNA molecule comprising a double-stranded structure that down-regulates expression of GAB2 (Growth factor receptor-bound protein 2 (GRB2) , where the siNA molecule does not require the presence of nucleotides having a 2'-hydroxy group within the siNA molecule for mediating RNA interference |
| 09/08/2005 | US20050196754 Nucleotide sequences coding modified immunoglobulin for use in immunodiagnostics and therapy |
| 09/08/2005 | US20050196443 Pulsatile release compositions and methods for enhanced intestinal drug absorption |
| 09/08/2005 | US20050196440 Mucoadhesive drug delivery devices and methods of making and using thereof |
| 09/08/2005 | US20050196428 Dilute aqueous solution containing epidermal growth factor in gel |
| 09/08/2005 | US20050196425 Synthetic peptides having a non growth factor heparin binding region, a linker, and sequences; treatment of bone lesions, degenerative joint disease and to enhance bone formation |
| 09/08/2005 | US20050196421 Preventing surgical adhesions, by delivering a tissue-reactive polymer, then a fibrosis-inhibiting agent to the coated tissue |
| 09/08/2005 | US20050196416 Dispersions prepared by use of self-stabilizing agents |
| 09/08/2005 | US20050196408 Stimulating an immune response in a primate utilizing bacterial adhesin proteins and/or imunogenic fragments |
| 09/08/2005 | US20050196407 Isolated polypeptide comprising a claimed amino acid sequence |
| 09/08/2005 | US20050196404 Gene is introducted into porcine cells folds properly and confers protection against human NK cell-mediated killing; polynucleotide, vector, antibody and the anti-idiotypic antibody |
| 09/08/2005 | US20050196403 Inducing cellular immune responses to p53 using peptide and nucleic acid compositions |
| 09/08/2005 | US20050196402 Immunoglobulin constant region modified to reduce mediated biological effector function relative to a CTLA4-IgG1 fusion protein; nucleic acids integrated into expression vectors direct synthesis of corresponding proteins in a variety of hosts; inhibit transplantation rejection, graft versus host disease |
| 09/08/2005 | US20050196399 antibody capable of specifically recognizing two regions of the A4 peptide/A beta 4, wherein the first region comprises the amino acid sequence AEFRHDSGY and the second region comprises the amino acid sequence YEVHHQKLVFFAEDVG |
| 09/08/2005 | US20050196392 Lesion repair polymerase compositions |
| 09/08/2005 | US20050196391 Method and composition for inhibiting cancer cell growth |
| 09/08/2005 | US20050196390 Detecting metalloproteinase inhibitor in sample of tissue, serum, urine, tumor; detectable label is a monoclonal antibody; radioimmunoassay, enzyme linked immunoassay |
| 09/08/2005 | US20050196389 Chlorella containing nutritional supplement having improved digestability |
| 09/08/2005 | US20050196385 Lymphocytic cells; industrial production of functional cells, pharmaceutical quality, large amounts; blood, plasma, serum from cytapheresis, frozen stock; cultured with synthetic activators phosphohalohydrin, phosphoepoxide, bisphosphonate,cytokine, interlukin; treat infection, parasites, cancer |
| 09/08/2005 | US20050196380 Immune response to chemokine, cytokine or immunomodulatory agent equivalent to intramuscular or subcutaneous delivery when administered over an extended period of time; multiple sclerosis; measuring the total antibody response against interferon beta |
| 09/08/2005 | US20050196379 Combination therapies with L-FMAU for the treatment of hepatitis B virus infection |
| 09/08/2005 | US20050196378 G-CSF conjugates |
| 09/08/2005 | US20050196374 Defecation deodorant |
| 09/08/2005 | US20050196359 Method and composition for treating oral bacteria and inflammation |
| 09/08/2005 | US20050196343 Degradable nanoparticles |
| 09/08/2005 | US20050196340 Synergistic mixtures; antitumor agents; anticancer agents |
| 09/08/2005 | DE10361813A1 Using hematopoietic growth factors for structural regeneration of tissue, useful e.g. for treating liver damage and wounds |
| 09/08/2005 | DE102004009400A1 Fibrinogen Reinigung Fibrinogen purification |
| 09/08/2005 | DE102004008417A1 Pharmaceutical active substance, for the treatment of cancers of liver, colon and kidney, comprises a peptide toxin, enzymes and alternatively antagonistically and/or synergistically active substance |
| 09/07/2005 | EP1571582A2 System for determining insulin dose using carbohydrate to insulin ratio and insulin sensitivity factor |
| 09/07/2005 | EP1571216A2 Phosphodiesterase 8A |
| 09/07/2005 | EP1571214A2 Immunogenic detoxified mutant toxin |
| 09/07/2005 | EP1571213A1 Bifidobacterium longum AR81 (KCCM-10492) enabling inhibition of rotavirus and active protein separated therefrom |
| 09/07/2005 | EP1571212A1 Recombinat protein containing albumin multimer |
| 09/07/2005 | EP1571159A1 Mutein of a bone morphogenetic protein and use thereof |
| 09/07/2005 | EP1571158A2 Globular assembly of amyloid beta protein and uses thereof |
| 09/07/2005 | EP1571157A1 LIPIN1 function |
| 09/07/2005 | EP1571155A1 Peptides and medicinal compositions containing the same |
| 09/07/2005 | EP1570859A2 Improved treatment of neovascularization |
| 09/07/2005 | EP1570855A1 Use of Botulinum toxin to inhibit hair growth |
| 09/07/2005 | EP1570854A1 Drug containing angiotensin convertase |
| 09/07/2005 | EP1570272A2 Identification of agonistic autoantibodies |
| 09/07/2005 | EP1570270A2 Therapeutic bioconjugates |
| 09/07/2005 | EP1570269A1 Methods of protecting against radiation damage using alpha thymosin |
| 09/07/2005 | EP1570087A1 Modulation of cd1d expression |
| 09/07/2005 | EP1570082A2 Modulation of notch2 expression |